Gene editing technologies

Gene-editing, and targeting capabilities of components of gene-editing systems, can be harnessed to provide wide-ranging, practical applications, yet freedom to operate issues often pose ongoing challenges for pioneers and start-ups in this fast-moving, powerful field.  

Whilst there is immense focus on CRISPR gene-editing, older techniques continue to have applications, with the early systems providing impetus for further developments in genetic modification in the CRISPR field and beyond.  

HGF has one of the most experienced, commercially- minded teams in Europe focussed on gene-editing, with significant experience of involvement in European oppositions affecting the foundational CRISPR IP,  as well as advising on and patenting earlier gene-editing systems, such as TALENs.  

The core team of specialists that make-up the HGF CRISPR team are backed by a larger group of over 75 patent attorneys and solicitors, with backgrounds in life sciences, pharmaceuticals, chemistry and plant sciences.  

Specialising in gene-editing in the context of new human and animal therapies, viral diagnostics, developments in animal farming and microbiome, as well as plant protection and breeding, the HGF CRISPR team includes specialists from the firm’s AgBio team. This enables HGF to develop multidisciplinary IP strategies across this important and complex field.  

HGF works with pioneers of CRISPR technology, as well as for clients advancing the field of gene modification and applications of CRISPR, to those that endeavour to resolve important problems, such as antibiotic resistance and infection diagnostics. This wealth of expertise sees HGF attorneys conducting talks at international events and providing articles on IP developments in the fast-evolving CRISPR field, along with the broader genetic engineering sector.

Latest updates

IAM Patent 1000 2023

IAM Patent 1000 the world’s leading patent professionals 2023 guide has now been published and we are delighted to have 31 attorneys recognised as world-class individuals in the guide. The …

Read article

What is EUDAMED and how will it affect your IP strategy?

The “European database on medical devices”, or “EUDAMED”, is the EU’s IT system created by the new Medical Devices Regulation (MDR) and In Vitro Diagnostics Medical Devices Regulation (IVDR). When …

Read article
Event - 8th-9th February 2023

5th Annual Microbiome & Probiotic Conference 2023

The 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference will take place in San Diego on the 8th-9th of February. This conference will enable you to learn about microbial …

Event details
Event - 29th November 2022

LSPN Europe 2022

HGF is a silver sponsor of LSPN Europe 2022 on 29th November in London. This event will explore some of the biggest challenges facing the Life Sciences Patent Community right now …

Event details

Food technology companies and investors - the value of IP landscape analysis

Case study – alt fat innovation Many companies and investors are aware of the importance of identifying and protecting their innovations, and in particular of the importance of obtaining patents …

Read article
Event - 22nd September 2022

BioCap Conference 2022

HGF is a gold sponsor at the BioCap Conference 2022. The conference will be held on Thursday 22 September at the Alderley Park Conference Centre. It connects life sciences businesses, …

Event details

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our gene editing technologies specialists.